Bausch Health Canadian Unit Adds PrOKEDI to Quebec Drug List
Bausch Health's Canadian subsidiary secures a RAMQ formulary listing for PrOKEDI, expanding patient access in Quebec.
Bausch Health's Canadian arm just scored a meaningful commercial win — getting PrOKEDI dosages listed on the RAMQ formulary, Quebec's public drug reimbursement list. For a specialty pharma name already navigating a complex balance sheet, any move that widens covered patient access is worth watching.
A RAMQ listing is no small administrative checkbox. Quebec's drug plan covers roughly half the province's population, so formulary inclusion directly translates into reimbursed prescriptions and, ultimately, real revenue flow. This kind of win can quietly shift volume numbers over the following quarters.
Read more Altman Calls Out Musk Over Space-Datacenter Hype as SPCX Slumps →
Bausch Health (BHC) trades with a heavy debt overhang, which means catalysts like this matter at the margin. Expanded formulary access in Canada won't single-handedly flip the thesis, but it chips away at the uncertainty around its subsidiary's revenue trajectory — especially as the company continues working toward a potential Bausch + Lomb separation and broader deleveraging story.
For traders watching BHC, the signal here is incremental but directionally positive. Formulary listings tend to build slowly then accelerate as physicians grow comfortable prescribing a covered product. Keep this one on the radar as a slow-burn commercial catalyst rather than an immediate pop.
Continue reading at Yahoo Finance
